The expression of cell-specialization genes is likely to be changing in tumor cells as their differentiation declines. Functional changes in these genes might yield unusual peptide epitopes with anti-tumor potential and could occur without modification in the DNA sequence of the gene. Melanomas undergo a characteristic decline in melanization that may ref lect altered contributions of key melanocytic genes such as tyrosinase. Quantitative reverse transcriptase-PCR of the wild-type (C) tyrosinase gene in transgenic (C57BL͞6 strain) mouse melanomas has revealed a shift toward alternative splicing of the pre-mRNA that generated increased levels of the ⌬1b and ⌬1d mRNA splice variants. The spontaneous c 2j albino mutation of tyrosinase (in the C57BL͞6 strain) changes the pre-mRNA splicing pattern. In c 2j ͞c 2j melanomas, alternative splicing was again increased. However, while some mRNAs (notably ⌬1b) present in C͞C were obligatorily absent, others (⌬3 and ⌬1d) were elevated. In c 2j ͞c 2j melanomas, the percentage of total tyrosinase transcripts attributable to ⌬3 reached approximately 2-fold the incidence in c 2j ͞c 2j or C͞C skin melanocytes. The percentage attributable to ⌬1d rose to approximately 2-fold the incidence in c 2j ͞c 2j skin, and to 10-fold that in C͞C skin. These differences provide a basis for unique mouse models in which the melanoma arises in skin grafted from a C͞C or c 2j ͞c 2j transgenic donor to a transgenic host of the same or opposite tyrosinase genotype. Immunotherapy designs then could be based on augmenting those antigenic peptides that are novel or overrepresented in a tumor relative to the syngeneic host.
(C57BL͞6 strain) mouse melanomas has revealed a shift toward alternative splicing of the pre-mRNA that generated increased levels of the ⌬1b and ⌬1d mRNA splice variants. The spontaneous c 2j albino mutation of tyrosinase (in the C57BL͞6 strain) changes the pre-mRNA splicing pattern. In c 2j ͞c 2j melanomas, alternative splicing was again increased. However, while some mRNAs (notably ⌬1b) present in C͞C were obligatorily absent, others (⌬3 and ⌬1d) were elevated. In c 2j ͞c 2j melanomas, the percentage of total tyrosinase transcripts attributable to ⌬3 reached approximately 2-fold the incidence in c 2j ͞c 2j or C͞C skin melanocytes. The percentage attributable to ⌬1d rose to approximately 2-fold the incidence in c 2j ͞c 2j skin, and to 10-fold that in C͞C skin. These differences provide a basis for unique mouse models in which the melanoma arises in skin grafted from a C͞C or c 2j ͞c 2j transgenic donor to a transgenic host of the same or opposite tyrosinase genotype. Immunotherapy designs then could be based on augmenting those antigenic peptides that are novel or overrepresented in a tumor relative to the syngeneic host.
Peptides recognized by cytotoxic T lymphocytes from melanoma patients have been found in a number of cases to originate from melanocyte-specific genes required for pigmentation, such as tyrosinase (1-3), tyrosinase-related protein 1͞gp75͞brown (4), tyrosinase-related protein 2͞slaty (5), Pmel17͞gp100͞silver (6) (7) (8) (9) , and MART-1͞Melan-A (10, 11) . In melanoma, these peptides appear to be acting as weak autoantigens. Their effectiveness as immunotherapeutic agents might be enhanced by experimentally augmenting their abundance, novelty, or presentation.
We have recently proposed a ''reverse'' route toward discovery of melanoma antigens that was prompted by the well known tendency of melanomas to become less pigmented in the course of malignant progression. It seemed possible that the pigmentary decline might be due to a change in RNA processing of some melanocytic genes. If splicing of any of the pre-mRNAs were, in fact, shifted from the constitutive mode toward particular alternative splicing modes, this would decrease the levels of proteins with essential roles in melanogenesis (relative to their incidence in normal melanocytes) and might increase the incidence of specific peptides with antigenic properties. Such functional modifications in RNA processing can occur without mutation in the gene under consideration-an important advantage in treatment designs directed against peptide products of that gene, because all the malignant cells then would be expected to have the same unchanged gene (12) .
The possibility of a selective increase in specific alternative transcripts was first investigated for the wild-type (C) tyrosinase gene in murine melanomas as compared with skin melanocytes (12) . Tyrosinase is the rate-limiting enzyme in melanin biosynthesis (13) . The murine gene has five exons and a variety of splicing patterns (14, 15) . Over 19 alternative mRNA splice variants were detected in skin melanocytes of the C57BL͞6 inbred strain, and a reliable protocol was established for quantitation of the mRNAs (S.R.K., N.L.F., and B.M., unpublished data). Melanomas in progressive stages of malignancy were then obtained from Tyr-SV40E (C57BL͞6 strain) transgenic mice (16) (17) (18) , in which the disease closely resembles human melanoma (19) . Analysis of the tyrosinase transcript profile in the mouse melanomas by quantitative reverse transcriptase (RT)-PCR clearly documented specific increases in alternatively spliced mRNAs, particularly the ⌬1b and ⌬1d sets, over their very low levels in normal skin melanocytes (12) . These transcripts represent deletions within the first exon.
A special feature of the transgenic mouse melanomas is that they can be experimentally elicited in several ways. The transgene alone acts only as an ''initiating'' stimulus conferring melanoma susceptibility; some additional (''promoting'') stimulus is needed for malignant skin melanomas to result. Conditions associated with wound healing were among those found to supply promoting stimuli. The melanomagenic effect was manifest after a small disc of skin was grafted from one transgenic animal to another (17) . When the skin-graft donor is from a transgenic line with high melanoma susceptibility (due to high expression of the transgene) and the host is from a relatively low-susceptibility line (with low expression of the same transgene), the tumors invariably arise in the grafted skin and metastasize into organs of the hosts. This grafting arrangement allows many novel and informative graft-host combinations to be carried out. For example, an allele can first be substituted for a gene of interest in either the donor or the host transgenic line by breeding animals of that line with mice of the relevant syngeneic histocompatible derivative of C57BL/6.
The c 2j albino mutation at the mouse tyrosinase locus provides an interesting opportunity of this sort, because the mutation changes the pattern of pre-mRNA splicing in comparison with that of the wild-type tyrosinase gene (20) . The c 2j mutation arose spontaneously in the C57BL͞6 strain. Molecular analysis of the gene in c 2j ͞c 2j albino skin disclosed a single change: a base substitution at an alternative splice donor site within exon 1. This abolishes the usage of that site for alternative splicing. Among several consequences shown in Fig. 1 is complete absence of ⌬1b mRNAs, which were previously found to be present at very low abundance in skin of the wild-type (C͞C) tyrosinase genotype and at relatively higher levels in C͞C melanomas (12) .
The objectives of the present study were to characterize the tyrosinase transcripts in c 2j ͞c 2j albino melanomas relative to c 2j ͞c 2j albino skin melanocytes; to compare the transcripts with those of C͞C melanomas and skin melanocytes (12) ; and to describe the graft-host combinations of C͞C and c 2j ͞c 2j genotypes in which qualitative or quantitative differences in specific alternative mRNAs may be favorable for model immunotherapy experiments.
MATERIALS AND METHODS
Skin Samples. Dorsal body skin was obtained from inbredstrain mice (Icr sublines) at 2-6 days of age. Mice of the standard C57BL͞6 strain are wild type at the tyrosinase locus while BALB͞c, FVB, and NFS strains have the classical (c) albino mutation. The albino C.B17 strain was derived in this institution from BALB͞c. Mice of the c 2j ͞c 2j albino C57BL͞6 strain were imported from The Jackson Laboratory, and a breeding colony was established here. c 2j ͞c 2j Melanomas. Cutaneous melanomas of the c 2j ͞c 2j albino genotype were experimentally produced by grafting discs of adult full-thickness body skin (17) taken from secondbackcross albino transgenic progeny of c 2j ͞c 2j mice and transgenic (C͞C) mice. Transgenic graft donors were highsusceptibility line 8 hemizygotes or, in one case, a hemizygote of the moderately susceptible line 9. Hosts were lowsusceptibility line 12 hemizygotes. Melanomas arose after an average latency of 35 weeks (range: 24-43 weeks) in the line 8 grafts, and after 73 weeks in the less susceptible line 9 graft. The cutaneous tumors averaged 797 mm 3 in size when they were collected. All had ulcerated and were invasive. Metastases were obtained in some cases. Pieces of the tumors were frozen in dry ice and stored at Ϫ70°C. Fourteen melanoma samples were analyzed; 11 were from separate primary tumors, and three were from metastases (one each from a regional lymph node, a lung, and a liver).
Amplification and Quantitation of Tyrosinase Transcripts. RNA was isolated from the transgenic tumors, or from dorsal body skin of nontransgenic mice, by the acid guanidinium thiocyanate-phenol-chloroform procedure (21) . Tyrosinase cDNAs were generated from 2.5 g of total RNA, and the products were amplified by RT-PCR as described (12) . A hot-start procedure (22) was used to prevent mis-priming. The same internal standard RNA as in the analysis of C͞C melanomas (12) was included in the RT reactions to serve as a reference in determining the levels of tyrosinase mRNA isoforms. The standard (corresponding to the full-length tyrosinase transcript with a 98-bp deletion in exon 1) was included at 100, 300, or 600 fg͞g cellular RNA so as to be present at approximately the level of the ⌬3 transcript in the Southern blot. Primers for RT and PCR, and probes for hybridizations, have been described (12) . Hybridizations were performed according to Church and Gilbert (23) . For each tumor sample, it was necessary to determine the number of PCR cycles that would provide sufficient amplification of all transcripts within the limits of the exponential phase. The number of cycles ranged from 21 to 25. Intensities of hybridizing bands were measured with a BAS1000 phosphorimager (Fuji).
RESULTS
Differences in Levels of the Full-Length Tyrosinase Transcript in c 2j ͞c 2j Melanomas vs. Skin Melanocytes. The fulllength (constitutively spliced) tyrosinase transcript was found at similar levels in nontransgenic c 2j ͞c 2j and C͞C skin melanocytes (Fig. 1) . The tyrosinase protein was virtually absent in c 2j ͞c 2j skin, possibly due to proteolytic degradation (20) . In c 2j ͞c 2j primary melanomas and their metastases, absolute levels of the full-length transcript varied but were higher in most cases than in c 2j ͞c 2j skin (Figs. 2 and 3 Left). In the c 2j ͞c 2j tumors there was an increase in specific alternatively spliced mRNAs (Tables 1 and 2 ). The combined chief alternative mRNAs were now as much as 29.5% of the total tyrosinase mRNAs in the tumors, as compared with 18.4% in skin (Table  1) . A shift from constitutive toward alternative splicing was also noted previously in the C͞C primary melanomas and metastases relative to C͞C skin (12) . Tyrosinase transcripts were not detected in a lung metastasis of c 2j ͞c 2j tumor 554P, although present in the skin tumor of origin (Table 2) .
Specific Increases in the ⌬3 and ⌬1d Alternative Splice Variants of Tyrosinase in c 2j ͞c 2j Primary Melanomas. The up-regulation of alternatively spliced transcripts in the c 2j ͞c 2j tumors was due mainly to specific increases in ⌬3, ⌬1d, and ⌬1d,3 alternative transcripts over their levels in skin; the sole exception was a slight decrease in ⌬1d of tumor 557P (Table  1) . [⌬3 represents deletion of exon 3; ⌬1d is a deletion within exon 1 (15) ; and ⌬1d,3 is a relatively minor codeletion of both ⌬1d and ⌬3. ⌬1d and ⌬1d,3 transcripts would have the same ORF and would therefore generate the same target peptide.] The ⌬3 mRNA was the most abundant splice variant in skin. It was further overexpressed in all the c 2j ͞c 2j tumors. ⌬3 largely accounted for the comigrating ⌬3/⌬4/⌬1e transcript group, which rose as high as 20.5% of total tyrosinase transcripts in the skin melanomas, as compared with 11.8% in skin mela- nocytes; ⌬1d increased to a maximum of 8.9%, as compared with 5.0% in skin; and ⌬1d,3 reached 2.1%, as compared with 0.9% in skin (Tables 1 and 2 ). In the cityscapes (Figs. 2 and 3 Right), alternative transcript levels are depicted relative to those of the full-length mRNAs in the same tumors; for these determinations, an equal amount of the full-length mRNA was loaded in each lane of the Southern blots.
The c 2j albino mutation, occurring at an alternative 5Ј splice donor site within exon 1 of the tyrosinase gene, precludes the usage of that site for pre-mRNA splicing. This eliminates the possibility of producing any of the ⌬1a or ⌬1b groups of transcripts, both of which are obtained in skin with the wild-type tyrosinase gene. At the same time, the usage of the next downstream alternative splice donor site within exon 1 is enhanced approximately 7-fold in c 2j over that in wild-type skin, resulting in increased levels of ⌬1c and ⌬1d mRNAs in c 2j ͞c 2j skin. However, the absolute levels of ⌬1c transcripts are low in any case (20) . The results for skin melanocytes that are relevant for the melanoma analyses are included in Fig. 1 . In the c 2j ͞c 2j melanomas, ⌬1a and ⌬1b transcripts are obligatorily absent and the ⌬1d transcript set is notably increased (Tables  1 and 2 Table 2 ). The transcript group due mainly to ⌬3 was also decreased in two of the metastases but was increased, surprisingly, in the liver metastasis of tumor 559 (Table 2) .
DISCUSSION
The tyrosinase transcripts found here in malignant mouse melanomas of the c 2j ͞c 2j albino genotype were all present in c 2j ͞c 2j skin melanocytes. A similar conclusion was reached for transcripts of the wild-type tyrosinase gene in C͞C melanomas as compared with C͞C melanocytes (12) . In both melanoma genotypes, there was a shift toward alternative splicing of the pre-mRNA, thereby increasing particular alternative splice variants in the tumors relative to skin melanocytes. Thus, in melanomas, the tyrosinase locus yields characteristic quantitative changes in mRNA isoforms that are allele-specific and are not due to de novo mutation in either of the investigated alleles. The high degree of consistency of these changes in the melanomas lends preliminary support to the general hypothesis that modified mRNA expression of lineage-specific normal genes may be common in many kinds of tumors; this, in turn, may enable candidate peptide targets for immunotherapy to be predicted (12) . Moreover, reliance upon overexpressed products of intact genes circumvents the problem that would be posed if a treatment strategy depended on genes subject in tumors to ongoing mutation.
Some melanomas farthest advanced in malignant progression may fail to express tyrosinase transcripts. This is evident from analyses of c 2j ͞c 2j tumors (Fig. 3 and Table 2 ) as well as C͞C tumors (12) . It therefore will be necessary to identify other melanocyte-lineage genes with overexpressed mRNA splice variants in these late stages to devise a vaccine cocktail of peptide antigens encompassing tumor cells in all stages. Judging from the RT-PCR data for C͞C melanomas, it appears that tyrosinasebased antigens may, in fact, be maximally effective only in the early stages of malignancy (12) . Northern and immunoblot analyses of C͞C melanomas from Tyr-SV40E transgenic mice have led to the same conclusion for tyrosinase mRNA and protein, respectively (24) . Those analyses also have identified at least one melanocytic gene, tyrosinase-related protein 2, which was expressed in all 10 tumor samples examined.
The main mRNA splice variants consistently overrepresented in the c 2j ͞c 2j melanomas were attributable to ⌬3 and the ⌬1d set (Figs. 2 and 3 Right; Tables 1 and 2 ). The alternative mRNAs generally overexpressed in C͞C melanomas were the ⌬1b and ⌬1d sets, whereas the ⌬3 variant was overexpressed in two-thirds of the tumors (12) . While ⌬1d mRNAs were elevated in both genotypic groups of melanomas, the comparative levels were unexpected. The ⌬1d level in c 2j ͞c 2j primary melanomas increased an average of 1.4-fold over the low basal level in c 2j ͞c 2j skin. This was not as high as the 2.4-fold average increase of ⌬1d in C͞C primary melanomas over the level in C͞C skin. One might have expected a greater increase in c 2j ͞c 2j melanomas in view of the fact that the ⌬1d level was 7-fold higher in c 2j ͞c 2j skin than in C͞C skin-the result of increased activation of a splice donor site in exon 1 located downstream of the site inactivated by the c 2j mutation (20) .
The c 2j albino mutation in the C57BL͞6 strain makes it possible to carry out model immunotherapy experiments based on quantitative as well as qualitative tyrosinase mRNA differences between a skin graft-hence, a melanoma actually developing in the graft-and its host. Other albino mutations, e.g., c (Fig. 1) , are known that alter pre-mRNA splicing due to a nucleotide change in the tyrosinase coding sequence, but the well characterized mutations are not in strains histocompatible with C57BL͞6. The need for graft-host histocompatibility might be circumvented by using a melanoma transplant line or cell line and inoculating it into an immunoincompetent host (e.g., nude or scid); however, this would bypass the role of the immune system. In addition, results would pertain to a longestablished tumor whose evolution was quite different from that of a primary tumor in its natural place. Radiation-induced albino mutations in mice also might be considered for experiments intended to exploit differences between melanomas and their hosts. But they are present in strains other than C57BL͞6, and also would be problematical because of chromosomal deletions extending upstream and͞or downstream of the tyrosinase gene (25) . Thus, a region at Ϸ15 kb upstream of the transcription initiation site that controls tyrosinase expression (26) could be compromised.
In Table 3 are shown experimental arrangements in which a host of either the C͞C or c 2j ͞c 2j tyrosinase genotype would have an opportunity to interact with a developing or progressing melanoma of the same or opposite syngeneic genotype. In all the genotypic combinations, specific tyrosinase alternative transcripts would be overrepresented in the melanoma cells relative to the host's melanocytes. In the last of the listed combinations, there also would be transcripts in the melanoma cells that are absent in the host; these are designated as ''foreign.'' The hosts then might be actively immunized against unusual peptides predicted from proteolytically processed products of the overexpressed or ''foreign'' splice variants that may bind well to class I major histocompatibility proteins of the C57BL͞6 strain (27) .
If the hosts bearing these skin grafts were to develop a strong spontaneous autoimmune response against antigenic peptides on *The 650P1 and 650P2 cases were independent tumors in the same skin graft. All other cases were single tumors in separate skin grafts. † In this group are most of the relatively abundant alternative transcripts detected by the prTyr probe, including the comigrating ⌬3͞⌬4͞⌬1e transcripts, ⌬1d, and ⌬1d,3, and excluding transcripts of low abundance (Ͻ0.1 molecule per ng of RNA). ‡ ⌬4 and ⌬1e transcripts are only minor components of this comigrating group. melanocytes within the grafts, it is evident that all melanocytes in the grafted skin would be destroyed and no melanomas would develop. We have by now carried out three of the four graft-host combinations in Table 3 (excluding grafts from c 2j ͞c 2j donors to c 2j ͞c 2j hosts) and have in fact obtained melanomas in a large percentage of the grafts (W.K.S. and B.M., unpublished data). This need not signify that the host's immune system fails to recognize melanocytic antigens that may be present, nor that the animal is tolerant of them. The occurrence of partial or incomplete tolerance has long been recognized. For example, immunological tolerance of histocompatibility antigens in murine skin allografts was clearly shown not to be an all-or-none phenomenon. All degrees of tolerance were found, ranging from a total and persistent inability to reject allografts to a minor delay in graft destruction (28) .
Our observations of pigmented (C͞C) transgenic skin grafts (in C͞C or c 2j ͞c 2j transgenic mouse hosts) suggest that a weak and delayed autoimmune response may be taking place. This appears to be indicated partly by the occasional regression of a tumor and partly by the gradual blanching of hairs in some grafts (W.K.S. and B.M., unpublished data). The latter effect is reminiscent of the patchy coats in mice immunized with a tyrosinase-related protein 1͞gp75 antigen (29) . Moreover, pale skin patches in human vitiligo patients with melanoma have been thought to be related to the presence of antityrosinase antibodies (30) .
Many practical issues remain to be resolved before an effective peptide-antigen tumor vaccine is obtained. That is the case whether the peptides are identified through T cell recognition (31) or by prediction from overexpressed mRNA isoforms in tumors. The recent identification of a human melanoma rejection antigen recognized by T cells as the product of an alternative transcript of the tyrosinase-related protein 1͞gp75 gene (32) implies that products of alternative transcripts may indeed play a role in tumor-host relations. The new murine models described here to evaluate tyrosinasebased antigens in melanoma provide a natural biological context in which to examine effects of vaccines on tumor development, progression, or metastasis. Comparable syngeneic mouse models with allelic differences between skin graft and host can be constructed to evaluate candidate melanoma antigens based on other loci, or to investigate antigens in other kinds of skin malignancies. 
